Peng Youmei, Cheng Tiefeng, Dong Lihong, Zhang Yuhai, Chen Xiaojing, Jiang Jinhua, Zhang Jingmin, Guo Xiaohe, Guo Mintong, Chang Junbiao, Wang Qingduan
Henan Key Laboratory for Pharmacology of Liver, Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China; College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou 450001, China.
Pharmaceutical College of Henan University, Kaifeng 475004, China.
J Pharm Biomed Anal. 2014 Sep;98:379-86. doi: 10.1016/j.jpba.2014.06.019. Epub 2014 Jun 20.
2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) is a novel pyrimidine analog that inhibits not only the replication of the hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV but also the replication of lamivudine-resistant HBV, 4'-azidocytidine or 2'-β-methylcytidine-resistant HCV, and nucleoside reverse-transcriptase inhibitor-resistant HIV variants. The present study was undertaken to evaluate the absolute oral bioavailability of FNC in rats and the pharmacokinetic properties of FNC after intragastric administration of single and multiple doses in rats and dogs. A sensitive high-performance liquid chromatography tandem quadrupole time-of-flight mass spectrometry (HPLC/Q-TOF MS) method and a reliable high-performance liquid chromatography tandem triple quadrupole mass spectrometry (HPLC/QqQ MS/MS) method were established for the determination of FNC in the rat and dog plasmas, respectively. The sample preparation involved a protein-precipitation method with methanol after the addition of lamivudine as an internal standard. FNC was analyzed by LC using a YMC-Pack Pro C18 column (150mm×4.6mm, 3μm) with methanol (containing 0.3% formic acid): 10mM ammonium acetate (containing 0.3% formic acid, pH 2.8) (35:65, v/v) as the mobile phase. Both mass spectrometers were equipped with an electrospray ionization interface in the positive-ion mode. The linear range was from 2.00 to 2000.00ngmL(-1) in rat plasma and 0.50 to 400.00ngmL(-1) in dog plasma. The intraday and interday precision were less than 10.55%, and the accuracy was in the range of -5.86 to 5.13%. The mean recoveries were greater than 82.70% and 82.97% for FNC and IS, respectively. The HPLC/Q-TOF MS and HPLC/QqQ MS/MS methods were both successfully applied in the pharmacokinetic studies of FNC in rats and dogs.
2'-脱氧-2'-β-氟-4'-叠氮胞苷(FNC)是一种新型嘧啶类似物,它不仅能抑制乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和HIV的复制,还能抑制对拉米夫定耐药的HBV、对4'-叠氮胞苷或2'-β-甲基胞苷耐药的HCV以及对核苷逆转录酶抑制剂耐药的HIV变体的复制。本研究旨在评估FNC在大鼠体内的绝对口服生物利用度以及在大鼠和犬单次及多次胃内给药后FNC的药代动力学特性。分别建立了灵敏的高效液相色谱串联四极杆飞行时间质谱(HPLC/Q-TOF MS)法和可靠的高效液相色谱串联三重四极杆质谱(HPLC/QqQ MS/MS)法用于测定大鼠和犬血浆中的FNC。样品制备采用加入拉米夫定作为内标后用甲醇进行蛋白沉淀的方法。使用YMC-Pack Pro C18柱(150mm×4.6mm,3μm),以甲醇(含0.3%甲酸):10mM醋酸铵(含0.3%甲酸,pH 2.8)(35:65,v/v)作为流动相,通过液相色谱分析FNC。两台质谱仪均配备电喷雾电离接口,采用正离子模式。在大鼠血浆中的线性范围为2.00至2000.00ng/mL,在犬血浆中的线性范围为0.50至400.00ng/mL。日内和日间精密度均小于10.55%,准确度在-5.86至5.13%范围内。FNC和内标的平均回收率分别大于82.70%和82.97%。HPLC/Q-TOF MS和HPLC/QqQ MS/MS方法均成功应用于FNC在大鼠和犬体内的药代动力学研究。